2022
Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis
Bregasi A, Freeman JV, Curtis JP, Akar JG, Ortiz-Leon XA, Maia JH, Higgins AY, Matthews RV, Sinusas AJ, McNamara RL, Sugeng L, Lin BA. Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis. AJP Heart And Circulatory Physiology 2022, 323: h559-h568. PMID: 35960632, PMCID: PMC9576173, DOI: 10.1152/ajpheart.00083.2022.Peer-Reviewed Original ResearchMeSH KeywordsAtrial AppendageAtrial FibrillationCardiac CatheterizationEchocardiography, TransesophagealHumansStrokeTreatment OutcomeVascular DiseasesConceptsLeft atrial appendage occlusionLA stiffnessAppendage occlusionLA appendageLA mechanicsTransesophageal echocardiographyPressure-volume analysisPercutaneous left atrial appendage occlusionAdverse atrial remodelingAtrial appendage occlusionLeft atrial appendageLA volume measurementsAtrial cardiomyopathyBaseline characteristicsLA complianceAtrial remodelingClinical outcomesAtrial appendageAtrial mechanicsCardiac performancePathophysiological roleBaseline parametersMagnitude of increaseAppendage sizeOcclusion
2020
2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Members W, Heidenreich P, Estes N, Fonarow G, Jurgens C, Kittleson M, Marine J, McManus D, McNamara R. 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation Cardiovascular Quality And Outcomes 2020, 14: e000100. PMID: 33284642, DOI: 10.1161/hcq.0000000000000100.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmerican Heart AssociationAtrial FibrillationAtrial FlutterCardiologyHumansQuality Indicators, Health CareUnited States
2016
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Heidenreich PA, Solis P, Estes NA, Fonarow GC, Jurgens CY, Marine JE, McManus DD, McNamara RL. 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Journal Of The American College Of Cardiology 2016, 68: 525-568. PMID: 27364541, DOI: 10.1016/j.jacc.2016.03.521.Peer-Reviewed Original Research
2008
ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration With the Heart Rhythm Society
Estes NA, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJ, Waldo AL, Wyse DG, Bonow RO, DeLong E, Goff DC, Grady K, Green LA, Hiniker A, Linderbaum JA, Masoudi FA, Piña IL, Pressler S, Radford MJ, Rumsfeld JS. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration With the Heart Rhythm Society. Journal Of The American College Of Cardiology 2008, 51: 865-884. PMID: 18294574, DOI: 10.1016/j.jacc.2008.01.006.Peer-Reviewed Original Research
2006
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. Cochrane Database Of Systematic Reviews 2006, 2010: cd001938. PMID: 17636690, PMCID: PMC10759270, DOI: 10.1002/14651858.cd001938.pub2.Peer-Reviewed Original ResearchConceptsAggregate odds ratioRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageOdds ratioDose warfarinMajor bleedsModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2001
Evidence-based Practice Centers: Production of Evidence Report on Management of Atrial Fibrillation
Robinson K, McNamara R, Bass E, Powe N. Evidence-based Practice Centers: Production of Evidence Report on Management of Atrial Fibrillation. AACN Advanced Critical Care 2001, 12: 618-627. PMID: 11759433, DOI: 10.1097/00044067-200111000-00018.Peer-Reviewed Original ResearchConceptsEvidence-based Practice CenterEvidence reportPractice centerAtrial fibrillationJohns Hopkins EvidenceEvidence-based careEvidence-based healthcareSpecific clinicSynthesis of evidenceSpecific patientHealthcare ResearchHealthcare practitionersIndividual basisFibrillationEvidence-based productsReportData abstractionPatientsGuidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Fuster V, Rydén L, Asinger R, Cannom D, Crijns H, Frye R, Halperin J, Kay G, Klein W, Lévy S, McNamara R, Prystowsky E, Wann L, Wyse D. Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. European Heart Journal 2001, 22: 1852-1923. PMID: 11601835, DOI: 10.1053/euhj.2001.2983.Peer-Reviewed Original ResearchAnticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. 2001, cd001938. PMID: 11279741, DOI: 10.1002/14651858.cd001938.Peer-Reviewed Original ResearchConceptsRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageDose warfarinMajor bleedsOdds ratioModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsAggregate odds ratioLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2000
Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials.
Miller M, McNamara R, Segal J, Kim N, Robinson K, Goodman S, Powe N, Bass E. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. The Journal Of Family Practice 2000, 49: 1033-46. PMID: 11093570.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Arrhythmia AgentsAtrial FibrillationEvidence-Based MedicineHumansMiddle AgedRandomized Controlled Trials as TopicConceptsAF conversionAtrial fibrillationSinus rhythmOdds ratioModerate evidenceMultiple antiarrhythmic agentsAdverse event ratesClinical trials databasesEfficacy of agentsAdverse event dataPharmacologic conversionAdverse eventsRandomized trialsTrials databasesCochrane CollaborationAntiarrhythmic agentsClinical trialsStudy qualityAgent efficacySuggestive evidenceEvent ratesFlecainideDisopyramideRelative efficacyStrong evidenceManagement of new onset atrial fibrillation.
McNamara R, Bass E, Miller M, Segal J, Goodman S, Kim N, Robinson K, Powe N. Management of new onset atrial fibrillation. Evidence Report Technology Assessment 2000, 1-7. PMID: 11471248, PMCID: PMC4781222.Peer-Reviewed Original ResearchAdultAge DistributionAgedAged, 80 and overAmbulatory CareAnti-Arrhythmia AgentsAnticoagulantsAspirinAtrial FibrillationClinical Trials as TopicComorbidityDecision Support TechniquesEchocardiographyElectric CountershockEvidence-Based MedicineFemaleHumansIncidenceMaleMiddle AgedPrognosisRisk FactorsSex DistributionSurvival RateThromboembolismTreatment OutcomePrevention of Thromboembolism in Atrial Fibrillation
Segal J, McNamara R, Miller M, Kim N, Goodman S, Powe N, Robinson K, Bass E, Center F. Prevention of Thromboembolism in Atrial Fibrillation. Journal Of General Internal Medicine 2000, 15: 56-67. PMID: 10632835, PMCID: PMC1495320, DOI: 10.1046/j.1525-1497.2000.04329.x.Peer-Reviewed Original ResearchConceptsAtrial fibrillationMajor bleedsStroke preventionMajor hemorrhageCochrane Collaboration's CENTRAL databaseAdditional major bleedsMore major bleedingMore major bleedsMore major hemorrhagePrimary stroke preventionPrevention of thromboembolismRisk of hemorrhageTrials of drugsCentral databaseMajor bleedingYounger patientsPrimary preventionMean agePatient riskBaseline riskStroke rateLower riskAspirinPatientsModerate evidenceThe evidence regarding the drugs used for ventricular rate control.
Segal J, McNamara R, Miller M, Kim N, Goodman S, Powe N, Robinson K, Yu D, Bass E. The evidence regarding the drugs used for ventricular rate control. The Journal Of Family Practice 2000, 49: 47-59. PMID: 10678340.Peer-Reviewed Original ResearchConceptsHeart rate controlExercise toleranceAtrial fibrillationHeart rateBetter heart rate controlCochrane Collaboration's CENTRAL databaseCalcium channel blocker verapamilAbstracts of trialsTrial of verapamilImproved exercise toleranceVentricular rate controlTrials of drugsEnglish-language articlesEnglish-language abstractsCentral databaseVentricular rateBlocker verapamilInsufficient evidenceSystematic reviewPlaceboFibrillationTrialsDrugsLanguage publicationsPatients